Novo is planning to broaden its pipeline by seeking out products that could be marketed more like consumer goods than conventional prescription medicines, according to STAT's Pharmalittle roundup. The brief item does not specify which therapeutic areas or commercial models the company is considering.
Separately, Alkermes has released early data related to ADHD, though the roundup gives no details on the size of the study or the results. Both items appear in the same news summary, so they are not connected beyond being pharmaceutical business updates.
Because there is only one source, there is no second account to confirm or challenge these reports. STAT presents both as short updates rather than full analyses.